Alliance submits comments to FDA on off-label use of oncolo...
Alliance submits comments to FDA on off-label use of oncology drugs
This week, the Ovarian Cancer National Alliance submitted comments to the Food and Drug Administration (FDA) about a proposed Guidance for Industry that could have the effect of limiting patient access to “off label” oncology drugs. In cancer, many people are prescribed treatments approved for other uses, but not currently approved for a particular disease. … Continued